Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an update.
Daito Pharmaceutical Co., Ltd. reported a 2.6% increase in net sales for the three months ended August 31, 2025, compared to the same period last year. The company also saw significant improvements in operating profit and profit attributable to owners of the parent, with increases of 17.6% and 12.8% respectively. These results reflect a positive financial trajectory and suggest a strengthening position within the industry, despite the exclusion of Daiwa Pharmaceutical Co., Ltd. from consolidation due to a merger.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1261.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating within the pharmaceutical industry. The company is primarily focused on the development, manufacturing, and distribution of pharmaceutical products.
Average Trading Volume: 72,427
Technical Sentiment Signal: Buy
Current Market Cap: Yen35.93B
For detailed information about 4577 stock, go to TipRanks’ Stock Analysis page.